Last reviewed · How we verify

NCT03214120

Does Modified Ultrafiltration Affect Thromboelastography Results?

Completed Last updated 4 October 2024
What this trial tests

trial in Congenital Heart Disease in 40 participants. Completed in 1 January 2019.

Timeline
8 January 2018
Primary endpoint
1 January 2019
1 January 2019

Quick facts

Lead sponsorWake Forest University Health Sciences
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date8 January 2018
Primary completion1 January 2019
Estimated completion1 January 2019
Sites1 location across United States

Conditions studied

Sponsor

Wake Forest University Health Sciences

Who can join

Adults 1 Day to 1 Month, any sex, with Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is to evaluate the effect of modified ultrafiltration on different components of Thromboelastography (TEG) in neonates undergoing cardiac surgery using cardiopulmonary bypass.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03214120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing